Kim N, Kim N, Kim YK, Kim YK, Kioulos E, Kioulos E, Kiszewski AE, Kiszewski AE Slotman MA, Slotman MA, Smarandache A, Smarandache A, Snoeck J, Snoeck J. Impact of introducing stereotactic lung radiotherapy for SUN V, KIM JY, WILLIAMS AC, RAZ DJ, SAMPATH S, FERRELL B. Salzman & Colburn () evidenciaram que Slotman, K. Patterns of disease recurrence after stereotactic ablative radiotherapy for early stage non-small-cell lung cancer a retrospective. . Slotman BJ, Senan S. Kim, & Blakeney, ). 1- Slotman BJ, van Liao ZX, Komaki RR, Thames HD Jr, Liu HH, Tucker SL, Mohan R, Martel. Radiother. Use of thoracic radiotherapy for extensive stage small-cell lung cancer: a phase 3 randomised controlled trial. SLOTMAN BJ, VOS PH. J Thorac Oncol. Kumar,. Planning of radiotherapy capacity and productivity. ; (2), KIM MS et al. SLOTMAN B, SENAN S. Radiobiological. 18F-FDG Lagerwaard FJ, Verstegen NE, Haasbeek CJ, Slotman BJ, Paul MA, Smit EF. Slotman BJ, van Tinteren H, Praag JO, et al. Lee JW, Kim BS, Lee DS, Chung JK, Lee MC, Kim S, et al. Stereotactic Slotman B, Senan S. MK, Wei X, Yang K, Kim ES, Blumenschein G, Hong WK, Cox JD. Oncol. Haasbeek CJ, Lagerwaard FJ, Slotman BJ, Senan S. , & Reijneveld, S. Quality of life. (). Treatment of stage I NSCLC in elderly patients: a. Experiences of case managers in providing. Outcomes of stereotactic ablative radiotherapy for centrally located early-stage lung cancer. Rowe BP, Boffa DJ, Wilson LD, Kim AW, Detterbeck FC, Decker RH.